Holen Sie sich die Stockscreener-App
1.02
6.42%
-0.07
Handel nachbörslich:
1.04
0.02
+1.96%
Schlusskurs vom Vortag:
$1.09
Offen:
$1.07
24-Stunden-Volumen:
290.63K
Relative Volume:
0.54
Marktkapitalisierung:
$37.38M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-9.16M
KGV:
-1.7895
EPS:
-0.57
Netto-Cashflow:
$-8.75M
1W Leistung:
-9.73%
1M Leistung:
-22.73%
6M Leistung:
+2.00%
1J Leistung:
-1.92%
1-Tages-Spanne:
$1.01
$1.0999
1-Wochen-Bereich:
$0.9834
$1.15
52-Wochen-Spanne:
$0.75
$1.6899
Renovorx Inc Stock (RNXT) Company Profile
Firmenname
Renovorx Inc
Sektor
Branche
Telefon
408-800-2649
Adresse
2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW
Vergleichen Sie RNXT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RNXT
Renovorx Inc
|
1.02 | 39.94M | 0 | -9.16M | -8.75M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Renovorx Inc Aktie (RNXT) Neueste Nachrichten
RenovoRx CEO Shaun Bagai to Participate at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum on November 20th - The Manila Times
RenovoRx (NASDAQ: RNXT) CEO Shaun Bagai to join Canaccord MedTech Forum on Nov 20 - Stock Titan
Is RenovoRx Inc. stock dividend yield sustainableFed Meeting & High Accuracy Swing Entry Alerts - newser.com
Intraday pattern recognizer results for RenovoRx Inc.2025 Risk Factors & Weekly Watchlist for Consistent Profits - newser.com
Is RenovoRx Inc. stock supported by innovation pipeline2025 Sector Review & Proven Capital Preservation Methods - newser.com
Tick level data insight on RenovoRx Inc. volatilityWeekly Volume Report & Entry and Exit Point Strategies - newser.com
Can RenovoRx Inc. stock deliver consistent earnings growthTrade Entry Report & Short-Term Trading Opportunity Alerts - newser.com
Using AI based signals to follow RenovoRx Inc.2025 Sector Review & Safe Entry Point Alerts - newser.com
Is RenovoRx Inc. stock attractive for income investorsMarket Movers & Advanced Swing Trade Entry Plans - newser.com
Can machine learning forecast RenovoRx Inc. recoveryJuly 2025 Recap & Safe Capital Investment Plans - newser.com
Does RenovoRx Inc. fit your quant trading modelMarket Risk Report & Capital Efficiency Focused Ideas - newser.com
Will RenovoRx Inc. stock attract ESG investorsJuly 2025 WrapUp & Daily Profit Focused Stock Screening - newser.com
What analyst consensus says on RenovoRx Inc. stock2025 Pullback Review & Accurate Intraday Trading Signals - newser.com
Should I hold or sell RenovoRx Inc. stock in 20252025 Support & Resistance & Fast Entry Momentum Trade Alerts - newser.com
Why RenovoRx Inc. stock remains on watchlists2025 Dividend Review & Risk Managed Investment Strategies - newser.com
How to integrate RenovoRx Inc. into portfolio analysis toolsQuarterly Trade Review & Short-Term High Return Strategies - newser.com
Evaluating RenovoRx Inc. with trendline analysisJuly 2025 Short Interest & Long-Term Growth Plans - newser.com
First Patient Treated in RenovoCath Clinical Trial - Medical Product Outsourcing
RenovoRx’s PanTheR Registry Trial: A New Frontier in Tumor Treatment - TipRanks
RenovoRx’s Innovative Approach in Pancreatic Cancer Treatment: A Clinical Study Update - TipRanks
RenovoRx to Host Third Quarter 2025 Financial Results and Business Highlights Conference Call on November 13th at 4:30 p.m. ET - The Manila Times
RenovoRx (Nasdaq: RNXT) to host Q3 2025 call; RenovoCath and Phase III TIGeR-PaC - Stock Titan
Finanzdaten der Renovorx Inc-Aktie (RNXT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):